Clinical studies reported that treatment of patients with osteoporosis with bisphosphonate or anti-RANKL antibody (denosumab) maintains bone mass through inhibition of bone resorption and helps lower the fracture rate9,53,54. Here, TNFSF11 is linked to osteoporosis.